2cureX AB publishes interim report for the first half-year of 2018

August 24 | 2018
2cureX AB (”2cureX”) hereby publishes the interim report for the first half-year of 2018. The interim report is available via attached file and on the company’s website (www.2curex.com). Below is a short summary of the report.

The first half-year (2018-01-01 until 2018-06-30) – the group

  • Net turnover for the period was 0 KSEK (0 KSEK).
  • The result after tax was -6 049 KSEK (-2 777 KSEK).
  • The result per share* was -0,58 SEK (-0,35 SEK).
  • The solidity** was 47 % (50 %).
  • The cash and bank was 27 838 KSEK (5 545 KSEK).

Second quarter (2018-04-01 till 2018-06-30) – the group

  • Net turnover for the period was 0 KSEK (0 KSEK).
  • The result after tax was -3 104 KSEK (-1 231 KSEK).
  • The result per share* was -0,30 SEK (-0,15 SEK).

*Result per share: The result of the period divided by the average number of shares. Average number of shares for the second quarter 2018:
10 350 000 shares. Total number of shares in 2cureX AB on June 30th, 2018: 10 350 000 shares.

**Solidity: Equity divided by total capital.

Significant events during the second quarter 2018

  • At the end of April 2018, 2cureX opened a screening laboratory in Hamburg, Germany, to prepare for the launch and commercialisation of IndiTreat® on the German market. 2cureX’s screening lab will become the prime contact for offering IndiTreat® testing to German oncology hospitals.
  • 2cureX published the annual report for the fiscal year 2017. The annual report is available on the website of 2cureX (www.2curex.com).
  • 2cureX announces that the company have initiated a clinical study in ovarian cancer with the University Hospital Rigshospitalet (Copenhagen) and the University Medical Center Hamburg-Eppendorf (Hamburg). The study consists of 40 patients and is expected to be finalized in 2018.
  • On 28 May 2018, the Annual General Meeting was held in 2cureX. Communication from the Annual General Meeting and a clarification regarding the warrants that were decided upon are available on the company's website (www.2curex.com).
  • At the end of June, 2cureX presents positive clinical data from its ongoing clinical study of IndiTreat at ESMO (European Society for Medical Oncology) in Barcelona.

Significant events after the end of the period

  • 2cureX is invited to participate at LSX (Life Science Executives, Leadership and Investment) Congress in Stockholm, 29th to 30th August 2018.
  • 2cureX strengthen its patent portfolio through the grant of European patent No. 3164709 “Identifying compounds modifying a cellular phenotype”.

Other events during the second quarter 2018

  • 2cureX participates in several conferences and investment events, including the People's Meeting in Bornholm, Aktiedagen in Stockholm and BioStock Live.
  • BioStock publishes an investment report for 2cureX and its product IndiTreat®.

CEO Ole Thastrup’s comments

"We have past the first half-year of 2018 and 2cureX has successfully further developed its operations and made a number of progresses in the second quarter of 2018. Among other things, we have expanded and opened a screening laboratory in Germany and initiated a study in ovarian cancer with well-reputed physicians at the hospitals in Copenhagen and Hamburg. In addition, we have also presented positive study results from the ongoing clinical validation study of IndiTreat®."

For the full interim report (only Swedish), please see https://www.2curex.com/investors/reports/

Certified Adviser

Sedermera Fondkommission is the Certified Adviser of 2cureX. 

For more information about 2cureX:

Ole Thastrup, CEO

E-mail: ot@2cureX.com

Phone: +45 22 11 53 99

URL: www.2curex.com

This is information that 2cureX AB is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication on the 24th of August, 2018.

About 2cureX

2cureX has developed a test called IndiTreat® (Individual Treatment Design), which is a patented method for selecting the right drug for the right patient. IndiTreat® establishes thousands of 3D micro-tumors that are functionally similar to the patient’s tumor. From a large panel of approved cancer treatments IndiTreat® selects the best treatment for the individual patient. IndiTreat® is expected to become a standard tool in the treatment design for cancer patients.

IndiTreat® is currently being clinically validated in colorectal cancer.

The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).

Previous Next